Surat Samachar

Homozygous Familial Hypercholesterolemia Market Analysis, Leading Companies, Emerging Drugs, and Epidemiology Forecast

 Breaking News
  • No posts were found

Homozygous Familial Hypercholesterolemia Market Analysis, Leading Companies, Emerging Drugs, and Epidemiology Forecast

April 22
04:17 2021
Homozygous Familial Hypercholesterolemia Market Analysis, Leading Companies, Emerging Drugs, and Epidemiology Forecast

Delveinsight Business Research LLP

DelveInsight’s “Homozygous Familial Hypercholesterolemia Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the Homozygous Familial Hypercholesterolemia, historical and forecasted epidemiology as well as the Homozygous Familial Hypercholesterolemia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Familial hypercholesterolaemia (FH) is an inherited disease leading to a very high serum cholesterol, present from birth, due to mutations affecting low density lipoprotein receptor (LDLR) activity. Most commonly, individuals have heterozygous familial hypercholesterolemia (HeFH), caused by a single DNA variant (alteration) for FH that they have inherited from one (affected) parent. 

Medications that are the mainstay of treatment for HeFH (such as statins) are relatively ineffective in HoFH. This is because the mechanism of action of statins normally “triggers” the liver to express additional LDL receptors. In the most severe cases of HoFH, the LDL receptors are completely inactive which makes this response futile. Statins can be effective in individuals with HoFH if there is some residual LDL-R activity, or if they have causal DNA variants in the APOB or PCSK9 genes.

Get FREE sample copy at: 
https://www.delveinsight.com/sample-request/homozygous-familial-hypercholesterolemia-market

The Homozygous Familial Hypercholesterolemia market report also covers emerging drugs, current treatment practices, Homozygous Familial Hypercholesterolemia market share of the individual therapies, current and forecasted Homozygous Familial Hypercholesterolemia Market Size from 2017 to 2030 segmented by seven major markets. 

The report provides a detailed current HoFH treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market. 

Homozygous Familial Hypercholesterolemia Market Key Facts

  • According to the American College of Cardiology, the US prevalence of probable/definite FH was estimated to be 0.40% (0.32-0.48) or 1 in 250 (1 in 311 to 209). 

  • A survey titled “Homozygous familial hypercholesterolemia (HoFH) in Germany: an epidemiological survey” by Walzer et.al., (2013) found that the estimated frequency of HoFH patients in Germany was around 95 (1:860,000).

Homozygous Familial Hypercholesterolemia Market

Key Benefits of Homozygous Familial Hypercholesterolemia Market Report

  • Homozygous Familial Hypercholesterolemia market report provides an in-depth analysis of Homozygous Familial Hypercholesterolemia Market Size, Share, Trend, Epidemiology and Market Forecast till 2030, in 7 major markets, i.e. EU5 (Germany, Italy, Spain, France, and the UK), Japan, and the United States.

  • The Homozygous Familial Hypercholesterolemia market report will help in developing business strategies by understanding the Homozygous Familial Hypercholesterolemia Market trends & developments, key players, and future market competition that will shape and drive the HoFH market in the upcoming years.

  • The Homozygous Familial Hypercholesterolemia market report covers Homozygous Familial Hypercholesterolemia current treatment practices, emerging drugs, market share of the individual therapies in 7 MM.

  • The report provides a detailed assessment of the HoFH market in terms of market drivers & barriers, Unmet Needs, market opportunities, patient population,  comparative analysis of pipeline products with detailed clinical profiles, and other factors. 

Homozygous Familial Hypercholesterolemia Market

The Homozygous Familial Hypercholesterolemia market outlook section of the report helps to build a detailed comprehension of the historic, current and forecasted Homozygous Familial Hypercholesterolemia market trends by analysing the impact of current therapies on the market, unmet needs, drivers, and barriers, and demand for better technology. 

The report gives a thorough detail of the Homozygous Familial Hypercholesterolemia market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders. 

Homozygous Familial Hypercholesterolemia Epidemiology

The HoFH epidemiology section covers insights about the historical and current Homozygous Familial Hypercholesterolemia patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.

It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.  

Homozygous Familial Hypercholesterolemia Drugs Uptake and Key Market Players

The HoFH Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Homozygous Familial Hypercholesterolemia market or expected to get launched in the market during the study period. The analysis covers Homozygous Familial Hypercholesterolemia market uptake by drugs; patient uptake by therapies; and sales of each drug.    

Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Few key players are involved in the therapeutics development of Homozygous Familial Hypercholesterolemia (HoFH). The HoFH market dynamics is anticipated to change in the coming years owing to the improvement in the research and development activities and the launch of efficient treatment options.

Homozygous Familial Hypercholesterolemia Companies:
Regeneron Pharmaceuticals
Novartis
LIB Therapeutics
NeuroBo Pharmaceuticals
Aegerion Pharmaceuticals
Amgen
And many others.

Homozygous Familial Hypercholesterolemia Therapies covered in the report include:
Evinacumab
Praluent
Inclisiran
LIB003
Gemcabene
Juxtapid (lomitapide)
Repatha (evolocumab)
And many more.

Table of Content

1. Key Insights

2. Executive Summary 

3. Homozygous Familial Hypercholesterolemia Competitive Intelligence Analysis

4. Homozygous Familial Hypercholesterolemia Market Overview at a Glance

5. Homozygous Familial Hypercholesterolemia Disease Background and Overview

6. Homozygous Familial Hypercholesterolemia Patient Journey

7. Homozygous Familial Hypercholesterolemia Epidemiology and Patient Population

8. Homozygous Familial Hypercholesterolemia Treatment Algorithm, Current Treatment, and Medical Practices

9. Homozygous Familial Hypercholesterolemia Unmet Needs

10. Key Endpoints of Homozygous Familial Hypercholesterolemia Treatment

11. Homozygous Familial Hypercholesterolemia Marketed Products

12. Homozygous Familial Hypercholesterolemia Emerging Therapies

13. Homozygous Familial Hypercholesterolemia Seven Major Market Analysis

14. Attribute Analysis

15. Homozygous Familial Hypercholesterolemia Market Outlook (7 major markets)

16. Homozygous Familial Hypercholesterolemia Access and Reimbursement Overview

17. KOL Views on the Homozygous Familial Hypercholesterolemia Market.

18. Homozygous Familial Hypercholesterolemia Market Drivers

19. Homozygous Familial Hypercholesterolemia Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The table of contents is not exhaustive; the final content may vary. 

Latest Reports By DelveInsight
Homozygous Familial Hypercholesterolemia Pipeline Insights
Homozygous Familial Hypercholesterolemia Pipeline Insights, 2021 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Homozygous Familial Hypercholesterolemia market.

US Healthcare Market Outlook
DelveInsight’s, “US Healthcare Outlook Report, 2020,” report provides comprehensive insights about healthcare scenario, regulatory policies and reimbursement landscape in the US. The report also identifies key trends in the healthcare market and provide insights into the demographic and healthcare infrastructure of the country. Along with this the report also provides a brief look into the trends and segmentation of the pharmaceutical and medical devices market of the US.

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: www.delveinsight.com/

Related Articles